HEMATOLOGY

Stephan Grupp, MD, PhD, discusses results of the phase II ELIANA study and the next steps with CAR T-cell therapy in ALL.

Pembrolizumab has been recommended for approval by the EMA’s Committee for Medicinal Products for Human Use for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.

The combination of rituximab, bendamustine, and low-dose cytarabine demonstrated a high complete response rate as an induction regimen for elderly patients with mantle cell lymphoma.

Pembrolizumab has been granted an accelerated approval by the FDA for the treatment of adult and pediatric patients with classical Hodgkin lymphoma who are refractory or have relapsed after 3 or more lines of therapy.

Clinical trials of selinexor, which is being explored in several tumor types, have been placed on clinical hold by the FDA.

A review of various frontline treatment options in follicular lymphoma and an outline of an algorithm for approaching patients with newly diagnosed follicular lymphoma.

Adding ublituximab to ibrutinib significantly improved objective response rates (ORR) compared with ibrutinib alone for patients with previously treated high-risk chronic lymphocytic leukemia .

The researchers discuss the rationale for checkpoint-based therapies including antibodies to PD-1/PD-L1 and CTLA-4, an overview of clinical experience with these agents, and future considerations and combinations of these agents.

Clinical holds on several phase I trials of vadastuximab talirine in acute myeloid leukemia have been lifted by the FDA.

Jennifer Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center at the Dana-Farber Cancer Institute, associate professor of Medicine at Harvard Medical School, discusses novel agents under investigation for the treatment of chronic lymphocytic leukemia (CLL).

A new drug application for enasidenib has been granted a priority review by the FDA as a treatment for patients with relapsed or refractory <em>IDH2</em>-mutated acute myeloid leukemia.

John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses studies investigating pacritinib for the treatment of myelofibrosis.

Worldwide clinical experience with the JAK1/2 inhibitor ruxolitinib in patients with myelofibrosis has yielded safety and efficacy data similar to results of a pivotal randomized trial.

Treating patients with intermediate/high-risk myelofibrosis with the Janus kinase inhibitor ruxolitinib long-term demonstrated improved survival, pooled data from 2 randomized trials showed.

An international patient survey showed patients with myeloproliferative disorders have a high symptom burden that significantly affects emotional status, quality of life, and functional ability.

Nathan Fowler, MD, associate professor, University of Texas MD Anderson Cancer Center, discusses managing patients with high-risk follicular lymphoma.

Michelle Fanale, MD, associate professor, University of Texas MD Anderson Cancer Center, discusses patient selection for newly approved agents in T-cell lymphoma.

Lenalidomide has been approved by the FDA as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant.

The anti-CD22 antibody-drug conjugate inotuzumab ozogamicin has been granted a priority review designation&nbsp;by the FDA for the treatment of patients with relapsed or refractory ALL.

A third of patients with previously treated, high- and intermediate-risk myelofibrosis had objective responses to the investigational second mitochondria-derived activator of caspases mimetic LCL161.

Multiple myeloma expert Kenneth C. Anderson, MD, will serve as president of the American Society of Hematology through the end of this year.

A full regulatory approval is being sought for blinatumomab as a treatment for patients with Philadelphia chromosome-negative relapsed/refractory B-precursor ALL.

Results from the phase I portion of the first trial testing axicabtagene ciloleucel, an autologous CD3&zeta;/CD28-based CAR T-cell therapy, indicate that the regimen can safely be administered and lead to durable CR after more than 12 months in refractory diffuse large B-cell lymphoma.

Philadelphia chromosome Ph&ndash;like acute lymphoblastic leukemia accounts for more than 20% of all adult patients with ALL and is associated with a poor outcome, according to findings published in the Journal of Clinical Oncology.

According to results of a phase I trial, the addition of the CDK 4/6 inhibitor palbociclib can help patients with mantle cell lymphoma overcome resistance to the BTK inhibitor&nbsp;ibrutinib.